Baiyunshan: The mouth-cleaning spray of the subsidiary company has obtained a drug supplementary application approval letter.

Baiyunshan announced that its subsidiary Heji Pharmaceutical Factory has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, approving the change in the drug specifications from "20ml per bottle" to "each 1ml equivalent to 240mg of herbal medicine, contains 13mg of menthol and 2.5l of eucalyptus oil." Heji Pharmaceutical Factory submitted the application on November 4, 2025, and it was accepted on November 17. As of the announcement date, approximately 2.4136 million yuan has been invested in the research and development of this drug. The domestic market sales in 2024 were 50.64 million yuan, and Heji Pharmaceutical Factory's sales revenue was 18.94 million yuan. The approval will have no significant impact on the current performance.